Molecular Types and Neoadjuvant Chemotherapy in Patients with Breast Cancer- While Molecular Shifting is More Common in Luminal a Tumors, The Pathologic Complete Response is Most Frequently Observed in Her-2 Like Tumors

Salim, Derya Kivrak; Mutlu, Hasan; Eryilmaz, Melek Karakurt; Musri, Fatma Yalcin; Tural, Deniz; Gunduz, Seyda; Coskun, Hasan Senol

추천

검색

자료유형: 학술저널

저자정보: Salim, Derya Kivrak (Department of Medical Oncology, Akdeniz University School of Medicine) Mutlu, Hasan (Department of Medical Oncology, Akdeniz University School of Medicine) Eryilmaz, Melek Karakurt (Department of Medical Oncology, Akdeniz University School of Medicine) Musri, Fatma Yalcin (Department of Medical Oncology, Akdeniz University School of Medicine) Tural, Deniz (Department of Medical Oncology, Akdeniz University School of Medicine) Gunduz, Seyda (Department of Medical Oncology, Akdeniz University School of Medicine) Coskun, Hasan Senol (Department of Medical Oncology, Akdeniz University School of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제21호

발행연도: 2014.1

수록면: 9,379 - 9,383 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Pathologic complete response (pCR) is one of the most important target end-points of neoadjuvant chemotherapy (NACT) in patients with breast cancer (BC). In present study, we aimed to investigate the relationship between molecular subtypes and NACT in patients with BC. Materials and Methods: Using the Akdeniz University database, 106 patients who received NACT for operable breast cancer were retrospectively identified. Prognostic factors before and after NACT were assessed. According to the molecular subtypes, molecular shifting after NACT and tumoral and nodal response to NACT were analyzed. Results: The distribution of subtypes was: Luminal A, 28.3% (n=30); Luminal B, 31.1% (n=33); HER2-like, 24.5% (n=26); and basal like/triple negative (BL/TN), 16.0% (n=17). According to molecular subtypes, pCR rates in both breast and axillary were 0%, 21.4%, 36.4% and 27.3% for luminal A, luminal B, HER2-like and BL/TN, respectively (p=0.018). Molecular subtype shifting was mostly seen in luminal A type (28.6%) after the NACT. The pCR rate in breast and axillary was significantly higher in patients with HER2-like type BC. Conclusions: In patients with HER-2 like type BC, NACT may be offered in early stages. Additionally, due to molecular shifting, adjuvant treatment schedule should be reviewed again, especially in the luminal A group.

#Breast cancer #molecular subtypes #neoadjuvant chemotherapy #response #molecular shifting

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요